Evaluation and Role of Single Chemotherapeutic Agents in Adult Non-Hodgkin’s Lymphoma

  • H. L. Davis
  • D. D. Von Hoff
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 65)

Abstract

The non-Hodgkin’s lymphomas are uniquely responsive to a broad range of chemotherapeutic agents of diverse chemical structure and mechanism of action. In the past decade, significant advances in histological diagnosis [86] and staging [20] have occurred documenting the importance of histology, nodal architecture, and stage upon intrinsic prognosis. Parallel to this, aggressive combination therapy has evolved and improved the prognosis in several subtypes, notably diffuse histiocytic and nodular mixed lymphocytic histiocytic lymphomas [15, 1]. In spite of these therapeutic advances, the majority of patients with non-Hodgkin’s lymphoma relapse and ultimately die. The purpose of this review is to reexamine the role of old and new drugs. Combination programs will be mentioned in an illustrative fashion; however, the emphasis will be on single agent activity and its relevance for future investigations.

Keywords

Methotrexate Cyclophosphamide Prednisone Pyrazole Piperazinedione 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adamson R. H., Canellos, G. P., Sieber, S. M.: Studies on the antitumor activity of gallium nitrate (NSC 15200) and other Group Ill-a metal salts. Cancer Chemother. Rep. 59, 599–610 (1975)PubMedGoogle Scholar
  2. 2.
    Alberto P., Gangji, D., Kenis, Y., Brugarolas, A., Clarysse, A., Sylvester, R., (EORTC Early Clinical Trials Group): Phase II Study of anhydro-ara-5 fluorocytidine (AAFC). Proc. AACR and ASCO 18, 231 (AACR abs. 923) (1977)Google Scholar
  3. 3.
    Altman S. J., Fletcher, W. S., Andrews, N. C., Wilson, W. L., Pischer, T.: Yoshi 864, a new Phase I study. Cancer 35,1145–1147 (1975)PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson T., De Vita, V., Bender, R., Mann, R., Chabner, B., Young, R.: Nodular lymphomas (NL): an important correlation of survival with complete remission induction. Proc. AACR and ASCO 18, 326 (ASCO abstr. C 238) (1977)Google Scholar
  5. 5.
    Andrews N. C., Weiss, A. J., Wilson, W., Nealon, T.: Phase II study of dibromodulcitol (NSC 104800). Cancer Chemother. Rep. 58,653–660 (1974)PubMedGoogle Scholar
  6. 6.
    Baker L. J., Samson, M. K., Izbicki, R. M.: Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas. Cancer Treat. Rep. 60, (9), 1389–1391 (Sept. 1976)PubMedGoogle Scholar
  7. 7.
    Beer C. T., Kajiwara, K., Mueller, G. C.: Synchronization of HeLa cells with 2,3-dihydro-lH- imidazo (l,2-b)-pyrazole. Biochem. Pharmacol, 23,1112–1115 (1974)CrossRefGoogle Scholar
  8. 8.
    Benjamin R. S., Hall, S. W., Burgess, M. A., Wheeler, W. L., Murphy, W. K., Blumenschein, G. R., Gottlieb, J. A.: A pharmacokinetically based Phase I-II study of single dose actinomycin D (NSC 3053). Cancer Treat. Rep. 60,289–291 (1976)PubMedGoogle Scholar
  9. 9.
    Berd D., Cornog, J., Di Conti, R., Levitt, M., Bertino, J. R.,: Long term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 55, 1050–1054 (1975)CrossRefGoogle Scholar
  10. 10.
    Bergsagel D. E., Cowan, D. H., Hasselback, R.: Plasma cell myeloma: response of melphalan- resistant patients to high dose intermittent cyclophosphamide. Can. Med. Assoc. J. 107, 851–855 (1972)PubMedGoogle Scholar
  11. 11.
    Bernard J., Jacquillat, Cl., Boiron, M., Weil, M., German, M. F., Izrael, V., Schaison, G., Delobel, J.: Cinquante-Sept. observations de leucemies aiques. Essai de traitmente par un derive semi-synthetique de la daunorubicine: le 22050 R.P. Nouv. Presse Med. 1, 2149–2152 (1972)PubMedGoogle Scholar
  12. 12.
    Blom J. and Cancer and Leukemia Group B: Treatment of stage II & IV diffuse lymphocytic and histiocytic lymphoma with vincristine/prednisone/bleomycin/streptonigrin induction, cyclophosphamide/vincristine/prednisone maintenance with and without consolidation with vinblastine/ CCNU/prednisone. Proc. AACR and ASCO 18, 332 (ASCO abstr. C-261) (1977)Google Scholar
  13. 13.
    Blum R. H., Carter, S. K., Agre, K.; A clinical review of bleomycin: a new antineoplastic agent. Cancer 31, 903–913(1973).PubMedCrossRefGoogle Scholar
  14. 14.
    Bonadonna G., De Lena, M., Monfardini, S., Bartoli, C., Bajetta, E., Baretta, G., Fossati- Bellani, F.: Clinical trials with bleomycin in lymphomas and solid tumors. Eur. J. Cancer 8,205–215 (1972)PubMedGoogle Scholar
  15. 15.
    Bonadonna G., Lattuada, A., Banfi, A.: Recent trends in the treatment of non-Hodgkin’s lymphomas. Eur. J. Cancer 12, 661–673 (1975)Google Scholar
  16. 16.
    Bonadonna G., Monfardini, S.: Chemotherapy of non-Hodgkin’s lymphomas. Cancer Treat. Rev. 1, 167–181 (1974)Google Scholar
  17. 17.
    Bonadonna G., Zucalli, R., Monfardini, S., De Lena, M., Vslenghi, C.: Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 36, 252–259 (1975)PubMedCrossRefGoogle Scholar
  18. 18.
    Cabanillas F., Rodriguez, V., Bodey, G. P., Benjamin, R. S.: Phase I-II study of maytansine (NSC 153,858). Proc. AACR and ASCO 18, 206 (AACR abstr. 823) (1977)Google Scholar
  19. 19.
    Capizzi R. L.: Improvement in the therapeutic index of methotrexate (NSC 740) by l-asparaginase (NSC 109229). Cancer Chemother. Rep. 6 (3), 37 1 (1975)Google Scholar
  20. 20.
    Carbone P. P., Kaplan, H. S., Musshof, K., Smithers, D. W., Tubiana, M.: Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 31, 1860–1861 (1971)PubMedGoogle Scholar
  21. 21.
    Carbone P. P., Spurr, C.: Management of patients with malignant lymphoma. A comparative study of cyclophosphamide and vinca alkaloids. Cancer Res. 28, 811–822 (1968)PubMedGoogle Scholar
  22. 22.
    Chabner B. A., Johnson, R. E., Young, R. C., Canellos, G. P., Hubbard, S. P., De Vita, V. T., Jr.: Sequential nonsurgical and surgical staging in non-Hodgkin’s lymphoma. Ann. Intern. Med.85, 149–154 (1976)PubMedGoogle Scholar
  23. 23.
    Chabner B., Levine, A., Adamson, R., Johnson, B., Whangpeng, J., Young, R.: Initial clinical and pharmacological studies of maytansine. Proc. AACR and ASCO 18, 129 (AACR abstr. 515) (1977)Google Scholar
  24. 24.
    Corbett T. H., Griswold, D. P.: Treatment of colon adencarcinomas in mice with anguidine (NSC-141537) and anguidine+ 5 -FU (NSC-19893). Proc. AACR and ASCO 18, 115 (AACR abstr. 457)(1977)Google Scholar
  25. 25.
    Creaven P. J., Allen, L. M., Cohen, M. H., Nelson, R. L.; Studies on the clinical pharmacology and toxicology of isophosphamide (NSC 109724). Cancer Treat. Rep. 60, 445–449 (1976)PubMedGoogle Scholar
  26. 26.
    Dawkins A. W., Grove, J. F., Tidd, B. K.: Diacetoxyscirpenol and some related compounds. Chem. Community 2, 27 (1965)Google Scholar
  27. 27..
    Djerassi I,. Kim, J. S.: Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin’s lymphomas) prolonged unmaintained remission. Cancer 38, 1043–1051Google Scholar
  28. 28.
    Durant J. R., Gams, R. A., Bartolucci, A. A., Dorfman, R. F.: BCNU 1with and without COP and cycle active therapy in non-Hodgkin’s lymphoma. Cancer Treat. Rep. (in press, 1977)Google Scholar
  29. 29.
    Ennis H. L., Moller, L., Wang, J. J., Selawry, O. S.: 2,3-dihydro-lH-imidazo (l,2-b)-pyrazole. A new inhibitor of deoxyribonucleic acid synthesis. Biochem. Pharmacol 20, 2639–2646 (1971)PubMedCrossRefGoogle Scholar
  30. 30.
    European Organization for Research on the Treatment of Cancer, Co-operative Group for Leukaemias and Haematosarcomas: Clinical Screening of epipodophyllotoxin VM 26 in malignant lymphomas and solid tumours. Br. Med. J. 2, 744–748 (1972)Google Scholar
  31. 31.
    Edzinli E., Pocock, S., Berard, C. W., Aungst, C. W., Silverstein, M., Horton, J., Bennett, J., Bakemeier, R., Stolbach, L., Perlia, C., Brunk, S. F., Lenhard, R. E., Klaasen, D. J., Richter, O., Carbone. P.: Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas. Cancer 38,1060–1068 (Sept. 1976)CrossRefGoogle Scholar
  32. 32.
    Falkson H. C., Falkson, G.: Phase II trial of cytembena in patients with advanced ovarian and breast cancer. Cancer Treat. Rep. 60 (11), 1655–1658 (1976)PubMedGoogle Scholar
  33. 33.
    Flannery E. P., Corder, M. P., Sheehan, W. W., Bateman, J. R.: Phase II evaluation of ICRF- 159 (NSC-129943) in non-Hodgkin’s lymphomas. Proc. AACR and ASCO 17, 289 (ASCO abstr. C- 209)(1976)Google Scholar
  34. 34.
    Frei E., III, Luce, J. K., Talley, R. W., Vaitkevicius, V. K., Wilson, H. E. 5 (3,3 dimethyl- triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Chemother. Rep. 56, 667–670 (1972)PubMedGoogle Scholar
  35. 35.
    Gottlieb J. A., Luce, J. K. Treatment of malignant melanoma with campothecin (NSC 100880). Cancer Chemother. Rep. 56, 103 (1972)PubMedGoogle Scholar
  36. 36.
    Green D., Sallan, S., Krishan, A.: Single dose actinomycin D in relapsed childhood leukemia. Proc. AACR and ASCO 18, 302 1977 (ASCO abstr. C-144)Google Scholar
  37. 37.
    Griffin R. L., Comis, R. L., Lokich, J., Canellos, G.: Neocarzinostatin: phase I study. Proc. AACR and ASCO 18, 302 (ASCO abstr. C-142) (1977)Google Scholar
  38. 38.
    Haas C., Goodwin, W., Leite, C., Stephens, R., Hoogstraten, B.: Phase I study of anguidine diacetoxyscirpenol (NSC 141537). Proc. AACR and ASCO 18, 296 (ASCO abstr. C-120) (1977)Google Scholar
  39. 39.
    Haas C. D., Stephens, R. L., Hollister, M., Hoogstraten, B.: Phase I evaluation of dianhydrogalactitol (NSC 132313). Cancer Treat. Rep. 60, 611–614 (1976)PubMedGoogle Scholar
  40. 40.
    Hayes D., Cvitkovic, E., Golbey, R., Scheiner, E., Krakoff, I. H.: Amelioration of renal toxicity of high dose eis platinum diammine dichloride (CPPD) by mannitol induced diuresis. Proc. AACE and ASCO 17, 169 (1976)Google Scholar
  41. 41.
    Helman L., Henney, J., Slavik, M.: Clinical brochure—anguidine (NSC 141537). Investigational Drug Branch Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.Google Scholar
  42. 42..
    Helman L., Henney, J., Slavik, M. Clinical brochure—Maytansine(NSC 153858). Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.Google Scholar
  43. 43.
    Hill J. M., Loeb, E., Pardue, A. S., Khan, A., Hill, N. O., King, J. J., Hill, R. W.: Platinum coordination compounds in the treatment of acute leukemia and other malignant diseases with particular reference to malanato 1,2-di-aminocyclohexane platinum (II). J. Clin. Haematol Oncology 7, 681–700 (1977)Google Scholar
  44. 44.
    Hoth D., Schein, P., McDonald, J., Buscaglia, D., Haller, D.: Phase I trial and clinical pharmacology of chlorozotocin (CL 2). Proc. AACR and ASCO 18, 309 (1977)Google Scholar
  45. 45.
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.: Ara-C-analogues. In: Minutes of New Drug Liaison Meeting 186–242 (Feb. 17–18, 1977)Google Scholar
  46. 46.
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.: Vindesine. In: Minutes of New Drug Liaison Meeting (Feb. 17–18,1977)Google Scholar
  47. 47.
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.: Pyrazolo imidazole. In: Minutes of the Phase I Working Group Meeting (Oct. 7,1976)Google Scholar
  48. 48.
    Israel M., Modest, E. J., Frei, E., Ill: N-trifluoroacetyl adriamycin-14-valerate—an analogue with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 35,1365–1368 (1975)PubMedGoogle Scholar
  49. 49.
    Jacobs E. M., Peters, F. C., Luce, J. K., Et Al: Mechlorethiamine (HCL) and cyclophosphamide in the treatment of Hodgkin’s disease and the lymphomas. JAMA 203, 392–398 (1969)CrossRefGoogle Scholar
  50. 50.
    Jacquillat Cl., Weill, M., Geman-Auclerc, M. F., Izrael, V., Bussed, A., Boiron, M., Bernard, T.: Clinical study of rubidazone (22050 R. P.), a new daunorubicin-derived compound, in 170 patients with leukemias and other malignancies. Cancer 37,653–659 (1976)PubMedCrossRefGoogle Scholar
  51. 51.
    Jacquillat Cl., Weil, M., Geman, M. F., Izrael, V., Schaison, G., Boiron, M., Bernard, J.: Treatment of acute myeloblasts leukemia with R.P. 22050. Br. Med. J. 4,468–469 (1972)PubMedCrossRefGoogle Scholar
  52. 52.
    Jones S. E., Fuks, Z., Bull, M., Kadin, M., Dorfam, R., Kaplan, H. S., Rosenberg, S. A.: Non- Hodgkin’s lymphomas IV—clinicopathologic correlation in 405 cases. Cancer 31, 806–823 (1973)PubMedCrossRefGoogle Scholar
  53. 53.
    Jones S. E., Salmon, S., Members of the Southwest Oncology Group: Phase II trial of piperazinedione (Crystal-line antibiotic) in lymphoma and multiple myeloma. Proc. AACR and ASCO17,45 (AACR abstr. 179) (1976)Google Scholar
  54. 52.
    Jones S. E., Salmon, S. E., Moon, T. E., s, Members of the Southwest Oncology Group (Swog): Chemo-immunotherapy of non-Hodgkin’s lymphoma (NHL). Proc. AACR and ASCO 18, 291 (ASCO abstr. C-100) (1977)Google Scholar
  55. 53.
    Jones S. E., Rosenberg, S. A., Kaplan, H. S., Kadin, M. E., Dorfman, R. F.: Non-Hodgkin’s lymphomas II. Single agent chemotherapy. Cancer 30, 31–38 (1972)PubMedCrossRefGoogle Scholar
  56. 56.
    Kaufman J. H., Ezdinli, E., Aungst, C. W., Stutzman, L.: Lymphosarcoma—a comparison of extended to conservative chemotherapy. Cancer 37,1283–1292 (1976)PubMedCrossRefGoogle Scholar
  57. 57.
    Kaufman J. H., Hanjina, G. L., Mittleman, A., Aungst, C. W., Murphy, G. P.: Study of LEO 1031 (NSC 134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. Cancer Treat. Rep. 60,277–279 (1976)Google Scholar
  58. 56.
    Kaufman J. H., Mittleman, A.: Clinical phase I trial of imosine dialdehyde (NSC 118954). Cancer Chemother. Rep. 59, 1007–1014 (1975)Google Scholar
  59. 57.
    Kennedy B. J., Hill, J., Bloomfield, C. D., Kiang, D., Fortuny, I., Theologides, A.: Combination (COP) versus successive single agent chemotherapy (C-O-P) in lymphocytic lymphoma. Proc. AACR and ASCO 16, 142 (AACR abstr. 568) (1975)Google Scholar
  60. 58.
    Krishan A., Frei, E., III, Paika, K,: Studies on the biological action of adriamycin analog, N- trifluoro-acetyl-adriamycin (AD 32). Proc. AACR and ASCO 18, 188 (AACR abstr. 751) (1977)Google Scholar
  61. 59.
    Laszlo J., Durant, J., Loeb, V.: Clinical pharmacological study of l-acetyl-2-picolinoylhydrazine (NSC 68626). Cancer Chemother. Rep. 53, 131–134 (1969)PubMedGoogle Scholar
  62. 60.
    Lauria F., Baccarani, M., Fiacchini, M.: Methotrexate cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin’s lymphoma. Eur. J. Cancer 11, 343–349 (1975)PubMedGoogle Scholar
  63. 63.
    Legha S. S., Slavik, M., Carter, S. K.: Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer 38, 27–35 (1976)PubMedCrossRefGoogle Scholar
  64. 64.
    Legha S. S., Von Hoff, D. D., Slavik, M., Muggia, F. M.: Neocarzinostatin (NSC 157365)—a new cancerostatic compound. Oncology 33, 265–270 (1976)PubMedCrossRefGoogle Scholar
  65. 65.
    Lenaz L., Page, J. A.: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev. 3, 111–120 (1976)CrossRefGoogle Scholar
  66. 66.
    Lenhard R. E., Jr., Prentice, R. L., Owens, A. H., Jr., Bakmeier, R., Horton, J. H., Shnider, B. I., Stolbach, L., Berard, C. W., Carbone, P.: Combination chemotherapy of the malignant lymphomas—a controlled clinical trial. Cancer 38, 1052–1059 (1976)PubMedCrossRefGoogle Scholar
  67. 67.
    Lias L. L., Kupchan, S. M., Horwitz, S. B.: Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol. Pharmacol. 12, 167–176 (1976)Google Scholar
  68. 68.
    Livingston R. B., Carter, S. K.: Single agents in cancer chemotherapy. New York-Washington- London: IFI/Plenum, 1970, p. 405Google Scholar
  69. 69.
    Mathé, G., Schwarzenberg, P., Pouillart, R., Oldham, R., Weiner, R., Jasmin, C., Rosenfeld, C., Hayat, M., Misset, J. L., Musset, M., Schneider, M., Amiel, J. L., De Vassal, F.: Two épipodophyllotoxin deratives, VN 26 and VP 16213, in the treatment of leukemias, hématosarcomas, and lymphomas. Cancer 34 (4), 985–992 (1974)PubMedCrossRefGoogle Scholar
  70. 70.
    Mathé, G., Schwartzenberg, P., Pouillart, P., Weiner, R., Oldham, R., Jasmin, C., Rosenfeld, C., Hayat, M., Schneider, M., Amiel, J. L., Céoara, B., Steresco-Musset, M., De Vassal, F.: Essai de traitment de divers hématosarcomes par le 4-déméthyl-épipodophyllotoxine ß D. thénylidème glucoside (VM 26 ou EPT). Nouve. Presse Med. 23, 447 51 (1974)Google Scholar
  71. 71.
    Mathé, G., Schwartzenbergerg, P., Pouillart, P., Weiner, R., Oldham, R., Jasmin, C., Rosenfeld, C., Hayat, M., Schneider, M., Amiel, J. L., Céoara, B., Steresco-Musset, M., De Vassal, F.: Leucémies aiguës et hématosarcomes divers. Essai de traitement par un second dérivé de la podophyllotoxine (le 4-demethyl-epipodophyllotoxine beta.D. ethylidene glucoside VP 16213 ou EPE). Nouv. Presse Med. 2, 521–524 (1974)Google Scholar
  72. 72.
    McKelvey E. M.: Gallium nitrate in minutes of the phase I working group meeting, April 26–27, 1977. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.Google Scholar
  73. 73.
    McKelvey E. M., Gottlieb, J. A., Wilson, H. E., Haut, A., Talley, R. W., Stephens, R., Lane, M., Gamble, J. F., Jones, S. E., Grozea, P. N., Gutterman, J., Coltman, C., Jr., Moon, T.: Hydroxyldaunomycin (adriamycin combination chemotherapy in malignant lymphoma. Cancer 38 (4), 1484–1493, (1976)PubMedCrossRefGoogle Scholar
  74. 74.
    Meyers G. E., McGuire, W., Young, R. C.: Adriamycin: amelioration of toxicity by a-tocopheral. Cancer Treat. Rep. 60, 961–962 (1976)Google Scholar
  75. 75.
    Misset J. L., Pouillart, P., Belpomme, L., Schwarzenberg, L., Delgado, M., Gil, M., Jasmin, C., Hayat, M., Mathé, G.: Combination chemotherapy with adriamycine, VM 26, cyclophosphamide and prednisone in lymphosarcoma and reticulosarcoma stage III and IV. Eur. J. Cancer 13, 411–414 (1977)PubMedGoogle Scholar
  76. 76.
    Moertel C. G., Schutt, et al.: Phase II study of campothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56, 95 (1972)Google Scholar
  77. 77.
    Möller, T. R., Brandt, L., Könynes, I., Lindberg, L. G.: Therapeutic effects of Leo 1031, an alkylating corticosteroid ester in lymphoproliferative disorders—II lymphocytic lymphoma. Acta Med. Scand.197, 323–327 (1975)PubMedCrossRefGoogle Scholar
  78. 78.
    Muggia F. M., Creaven, P. J., Hansen, H. H., Et Al; Phase I clinical trial of weekly and daily treatment with campothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother. Rep. 5(5,515–521 (1972)Google Scholar
  79. 79.
    O’connell, M. J., Silverstein, M. J., Silverstein, M. N., Kiely, J. M., White, W. L.: Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomas. Cancer Treat. Rep. 57,(1), 65–68 (1977)Google Scholar
  80. 80.
    O’bryan, R. M., Baker, L. H., Gottlieb, J. A., Rivkin, S. E., Balcerak, S. P., Grumet, G. N., Salmon, S. E., Moon, T. E., Hoogstraten, B.: Dose response evaluation of adriamycin in human neoplasia. Cancer 39, 1940–1948 (1977)PubMedCrossRefGoogle Scholar
  81. 81.
    O’Bryan, R. M., Luce, J. K., Talley, R. W., Gottlieb, J. A., Baker, L. J., Bonadonna, G.: Phase II evaluation of adriamycin in human neoplasia. Cancer 32, 1–8 (1973)PubMedCrossRefGoogle Scholar
  82. 82.
    Page R. H., Talley, R. W., Bukagiar, J.: The enhanced anti-tumor activity of cis-diammedichlo- roplatinum (II) against murine tumors when combined with other agents. J. Clin. Haematol. Oncology 7, 96–104 (1977)Google Scholar
  83. 83.
    Perevodchikova N. I., Gorbunova, V. A., Lichinitser, M. P., Borisov, V. I., Alekseev, N. A., Vygodskaya, L.: Phase I clinical trial of carminomycin in a new anthracycline antibiotic. Proc. AACR and ASCO (AACR abstr 437) 77, 110 (1976)Google Scholar
  84. 84.
    Pittman S., Frei, E., Ill: Weekly methotrexate citrovorum (MTX-CF) with alkalinization: tumor response in a phase II study. Proc. AACR and ASCO 18, 124 (AACR abstr. 494) (1977)Google Scholar
  85. 85.
    Portlock C. S., Rosenberg, S. A., Glatstein, E., Kaplan, H. S.: Treatment of advanced non- Hodgkin’s lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47, 747–756 (1976)PubMedGoogle Scholar
  86. 86.
    Rappaport H.: Tumors of the hematopoetic system. In: Atlas of Tumor Pathology, Sec. 3, Fasc. 8. Washington, D.C.: Armed Forces Institute of Pathology, 1966Google Scholar
  87. 87.
    Remillard S., Et Al: Antimitotic activity of the potent tumor inhibitor maytansine. Science 189, 1002–1005 (1975)PubMedCrossRefGoogle Scholar
  88. 88.
    Rozencweig M., Von Hoff, D. D., Slavik, M., Muggia, F. M.: Cis-diamminedichloroplatinum II: a new anticancer drug with significant clinical activity. Ann. Intern. Med. 86, 803–812 (1977)PubMedGoogle Scholar
  89. 89.
    Schein P. S., Chabner, B. A., Canellos, G. P., Young, R. C., Berard, C. W., De Vita, V. T., Jr.: Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin’s lymphomas. Blood 43, 181–190 (1974)PubMedGoogle Scholar
  90. 90.
    Schein P. S., De Vita, V. T., Jr., Hubbard, S., Chabner, B. A., Canellos, G. P., Berard, C., Young, R. C.: Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) in the treatment of advanced diffuse histiocytic lymphoma. Ann. Intern. Med.85, 417–422 (1976)PubMedGoogle Scholar
  91. 91.
    Schein P. S., O’Connell, M. J., Blom, J., Hubbard, S., Magrath, I. T., Bergevin, P., Wiernik, P. H., Ziegler, J. L., De Vita, V. T.: Clinical antitumor activity and toxicity of streptozotocin (NSC-85998) Cancer 34, 993–1000 (1974)PubMedGoogle Scholar
  92. 92.
    Schein P. S., Panasci, L., Woolley, P. V., Anderson, T.: Pharmacology of chlorozotocin (NSC- 178248), a new nitrosourea antitumor agent. Cancer Treat. Rep. 60, 801–805 (1976)Google Scholar
  93. 93.
    Sieber S. M., Mead, J. A. R., Adamson, R. H.: Pharmacology of antitumor agents from higher plants. Cancer Treat. Rep. 60, 1127–1139 (1976)Google Scholar
  94. 94.
    Spear P. W., Patno, M. E.: A comparative study of the effectiveness of HN2 and cyclophosphamide in bronchogenic carcinoma, Hodgkin’s disease and lymphosarcoma. Cancer Chemother. Rep. 16, 413–415(1962)PubMedGoogle Scholar
  95. 95.
    Stein T. S., Moran, E. M., Desser, R. K., Miller, J. B., Golomb, H. M., Ultman, J. E.: Combination chemotherapy of lymphomas other than Hodgkin’s disease. Ann. Intern. Med.81, 601 (1974)PubMedGoogle Scholar
  96. 96.
    Stolinsky D. C., Jacobs, E. M., Irwin, L. E., Bateman, J. R.: Study of trimethylcolchicinic acid methyl ether d-tartrate (TMCA; NSC.-36354) in Hodgkin’s and non-Hodgkin’s lymphoma. Proc. AACR and ASCO 77, 237 (ASCO abstr. C-l) (1976)Google Scholar
  97. 97.
    Stitzman L., Ezdinli, E. Z., Stutzman, M. A.: Vinblastine sulfate vs. cyclophosphamide in the therapy of lymphoma. JAMA 195, 173–178 (1966)Google Scholar
  98. 98.
    Sutow W. W., Komp. D., Vietti, T. J., Pinkerton, D.: Clinical trials with l-acetyl-2- picolinoylhydrazine (NSC-68626) in children. Cancer Chemother. Rep. 59, 341–344 (1975)Google Scholar
  99. 99.
    Von Hoff, D. D., Rozencweig, M., Soper, W. T., Helman, L. J., Davis, H. L., Penta, J. S., Muggia, F. M.: Whatever happened to NSC ? Cancer Treat. Rep. 61, 759–768 (1977)Google Scholar
  100. 100.
    Weiss A. J., Metter, G. E., Fletcher, W. S., Wilson, W. L., Grage, R. B., Ramirez, G.; Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. 60, 813–822 (1976)Google Scholar
  101. 101.
    Wilkinson P. M., Israel, M., Pegg, W. J., Frei, E., Ill: Comparative hepatobiliary metabolism and excretion of adriamycin (ADR) and n-tri-flouroacetyladriamycin-14-valerate (AD-32). Proc. AACR and ASCO 18, 188 (AACR abstr. 752) (1977)Google Scholar
  102. 102.
    Wilson W. L., Weiss, A. J., Frelich, R. W.: A phase III study in lung cancer comparing hexamethylmelamine with dibromodulcital. Oncology 31, 289–305 (1975)CrossRefGoogle Scholar
  103. 103.
    Winchell H. S., Sanchez, P. D., Watanabe, C. K., Hollander, L., Auger, H. O., McCrae, I.: Visualization of tumors in humans using 67Ga-citrate and the Auger whole-body scanner, scintillation camera and tomographic scanner. J. Nucl. Med.11, 459–466 (1970)PubMedGoogle Scholar
  104. 104.
    Wollner N., Burchenal, J. H., Lieberman, P. H., Exelby, P., D’Angio, G. J., Murphy, M. L.: Non Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer 37, 123–134(1976)PubMedCrossRefGoogle Scholar
  105. 105.
    Worzolla J. F., Kaiman, B. D., Johnson, B. M., Ramirez, G., Bryan, G. T.: Metabolism of hexamethylmelamine-ring C in rats and man. Cancer Res. 34, 2669–2674 (1974)Google Scholar
  106. 106.
    Yang S. S.: Rifamycin antibiotics: Inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts. J. Natl. Cancer Inst. 49, 7–25 (1972PubMedGoogle Scholar
  107. 107.
    Zbinden G., Brandle, E.: Toxicologic screening of daunorubicin (NSC 82151), adriamycin (NSC 123127) and their derivatives in rats. Cancer Chemother. Rep. 59, 707–715 (1975)Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • H. L. Davis
  • D. D. Von Hoff

There are no affiliations available

Personalised recommendations